Five of the world’s biggest drugs companies have agreed to slash the price of
their anti-HIV drugs in developing countries by 85 per cent following sustained
pressure from health agencies, Third World governments and patient groups
(¿ìè¶ÌÊÓƵ, 29 April, p 14).
One of the companies, Glaxo Wellcome, is
cutting the price of triple drug therapy from $16 to $2 a day. But
pressure groups have warned that even at these prices, poverty and a lack of
health infrastructure in poor countries will mean the benefits are limited.
To continue reading, today with our introductory offers
Advertisement
More from ¿ìè¶ÌÊÓƵ
Explore the latest news, articles and features
Popular articles
Trending ¿ìè¶ÌÊÓƵ articles
1
The best new science-fiction books of June 2026
2
Pancreatic cancer halted by virus injection in three patients
3
Glaciers in the 'roof of the world' have suddenly started melting
4
Red-light therapy does have health benefits but not the ones you think
5
Q-Day could destroy bitcoin – and our retirement savings
6
Mathematical AI helps researchers crack 50-year-old problem
7
Millions of planets might form around supermassive black holes
8
Surprising male G-spot found in most detailed study of the penis yet
9
How a radical new view of life could reveal its origin – and aliens
10
Embryos made without sperm or eggs reveal why many pregnancies fail
